
IndraLab
Statements
Hydroxychloroquine inhibits COVID-19. 51 / 51
5
|
2
44
reach
"We therefore aim to conduct the first randomized placebo-controlled trial of HCQ to prevent COVID-19 infections in front line health care workers at high risk of SARS-CoV-2 exposure as we prepare for escalating rates of COVID-19 in Toronto, Canada.The HEROS study is a double-blind, randomized placebo controlled trial of oral HCQ 400 mg taken once daily for three months as PrEP to prevent COVID-19 in front line health care workers at high risk for SARS-CoV-2 exposure."
reach
"36 Interestingly, computer simulations suggest that hydroxychloroquine and chloroquine are predicted to bind to the active site of the enzyme UDP-N-acetylglucosamine 2-epimerase, which catalyzes the rate determining step in the sialic acid biosynthesis pathway, 37 and thus there is a rational basis to assume hydroxychloroquine can interfere in terminal glycosylation of proteins in the Golgi apparatus.In a small unrandomized clinical cohort of 80 patients the combination of hydroxychloroquine and azithromycin has been shown to rapidly reduce viral load in COVID-19 patients and ameliorate clinical symptoms in the majority of patients."
reach
"Another concern of this study is that about 60% HCQ-treated patients received azithromycin simultaneously, which increases risk of QT-interval prolongation and sudden death.In summary, this retrospective study demonstrates that HCQ significantly reduces death risk of critically ill COVID-19 patients without apparent toxicity, and its mechanism of action is likely mediated through its inhibition of inflammatory cytokines on top of its ability in inhibiting viral replication."
reach
"Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic."
reach
"This study demonstrates that HCQ, a less toxic derivative of CQ, has dramatically decreased the fatality of critically ill patients of COVID-19 by attenuating the inflammatory cytokine storm.From February 1, 2020 to April 4, 2020, a total of 550 critically ill COVID-19 patients were admitted to Tongji Hospital, including 344 males and 206 females."
reach
"It is worth highlighting that the authors of the studies assessing the in vitro antiviral effect of CQ and HCQ point out that the relatively low safety index of these drugs warrants a cautious approach when designing any clinical trials.1,2An open-label non-randomized clinical trial suggested that HCQ treatment reduces viral load in COVID-19 patients, and this effect is reinforced using azithromycin."
reach
"However, in many other countries (the USA, UK, and EU countries) did not resort to any such measures.Anti-malarial drug hydroxychloroquine was suggested to reduce the COVID-19 risk in health workers with potential for retinal and cardiac toxicity.This drug has diverse modes of action, including inhibition of cytokine storms in the host cell which work against the viral infections and help prevent deaths."
| PMC
reach
"Hydroxychloroquine inhibits SARS-CoV-2unpublished study of 62 COVID-19 patients, undertaken after the observation that none of a cohort 80 lupus patients in Wuhan on chronic hydroxychloroquine therapy developed COVID-19 infection, 62 patients with mild COVID-19 symptoms and signs of COVID-19 pneumonia on CT scan were randomized to 200mg of hydroxychloroquine orally twice daily for 5 days and usual care or usual care alone."
reach
"This study confirmed that both CQ and HCQ can interact with ACE2 and inhibit the entry of pseudoviruses.CQ has been reported to be an endocytosis blocking agent, and can inhibit ZIKA virus infection in different cell models [23] , similarly, COVID-19 was driven by endocytosis after binding to ACE2, and was blocked by CQ and HCQ."
| DOI